Literature DB >> 19740899

Early prenatal androgenization results in diminished ovarian reserve in adult female rhesus monkeys.

D A Dumesic1, M S Patankar, D K Barnett, T G Lesnick, B A Hutcherson, D H Abbott.   

Abstract

BACKGROUND: Early prenatal androgenization (PA) accelerates follicle differentiation and impairs embryogenesis in adult female rhesus monkeys (Macaca mulatta) undergoing FSH therapy for IVF. To determine whether androgen excess in utero affects follicle development over time, this study examines whether PA exposure, beginning at gestational days 40-44 (early treated) or 100-115 (late treated), alters the decline in serum anti-Mullerian hormone (AMH) levels with age in adult female rhesus monkeys and perturbs their ovarian response to recombinant human FSH (rhFSH) therapy for IVF.
METHODS: Thirteen normal (control), 11 early-treated and 6 late-treated PA adult female monkeys had serum AMH levels measured at random times of the menstrual cycle or anovulatory period. Using some of the same animals, basal serum AMH, gonadotrophins and steroids were also measured in six normal, five early-treated and three late-treated PA female monkeys undergoing FSH therapy for IVF during late-reproductive life (>17 years); serum AMH also was measured on day of HCG administration and at oocyte retrieval.
RESULTS: Serum AMH levels in early-treated PA females declined with age to levels that were significantly lower than those of normal (P < or = 0.05) and late-treated PA females (P < or = 0.025) by late-reproductive life. Serum AMH levels positively predicted numbers of total/mature oocytes retrieved, with early-treated PA females having the lowest serum AMH levels, fewest oocytes retrieved and lowest percentage of females with fertilized oocytes that cleaved.
CONCLUSIONS: Based on these animals, early PA appears to program an exaggerated decline in ovarian reserve with age, suggesting that epigenetically induced hormonal factors during fetal development may influence the cohort size of ovarian follicles after birth.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19740899      PMCID: PMC2777787          DOI: 10.1093/humrep/dep324

Source DB:  PubMed          Journal:  Hum Reprod        ISSN: 0268-1161            Impact factor:   6.918


  55 in total

1.  Increased oocyte degeneration and follicular atresia during the estrous cycle in anti-Müllerian hormone null mice.

Authors:  Jenny A Visser; Alexandra L L Durlinger; Isolde J J Peters; Edwin R van den Heuvel; Ursula M Rose; Piet Kramer; Frank H de Jong; Axel P N Themmen
Journal:  Endocrinology       Date:  2007-01-25       Impact factor: 4.736

2.  Serum anti-Mullerian hormone as a surrogate for antral follicle count for definition of the polycystic ovary syndrome.

Authors:  P Pigny; S Jonard; Y Robert; D Dewailly
Journal:  J Clin Endocrinol Metab       Date:  2005-12-20       Impact factor: 5.958

3.  Impact of gonadotrophin stimulation for assisted reproductive technology on ovarian ageing and menopause.

Authors:  Kay Elder; Thomas Mathews; Ellen Kutner; Eujin Kim; Donna Espenberg; Malcolm Faddy; Roger Gosden
Journal:  Reprod Biomed Online       Date:  2008-05       Impact factor: 3.828

4.  Fertilization and cleavage of rhesus monkey oocytes in vitro.

Authors:  B D Bavister; D E Boatman; L Leibfried; M Loose; M W Vernon
Journal:  Biol Reprod       Date:  1983-05       Impact factor: 4.285

Review 5.  Culture and selection of viable blastocysts: a feasible proposition for human IVF?

Authors:  D K Gardner; M Lane
Journal:  Hum Reprod Update       Date:  1997 Jul-Aug       Impact factor: 15.610

6.  Anti-Mullerian hormone levels reflect severity of PCOS but are negatively influenced by obesity: relationship with increased luteinizing hormone levels.

Authors:  Athanasia Piouka; Dimitrios Farmakiotis; Ilias Katsikis; Djuro Macut; Spiros Gerou; Dimitrios Panidis
Journal:  Am J Physiol Endocrinol Metab       Date:  2008-10-28       Impact factor: 4.310

7.  Anti-Müllerian hormone serum concentrations in normoovulatory and anovulatory women of reproductive age.

Authors:  Joop S E Laven; Annemarie G M G J Mulders; Jenny A Visser; Axel P Themmen; Frank H De Jong; Bart C J M Fauser
Journal:  J Clin Endocrinol Metab       Date:  2004-01       Impact factor: 5.958

Review 8.  Mullerian Inhibiting Substance is an ovarian growth factor of emerging clinical significance.

Authors:  David B Seifer; David T Maclaughlin
Journal:  Fertil Steril       Date:  2007-06-07       Impact factor: 7.329

9.  Changes in serum anti-mullerian hormone level during low-dose recombinant follicular-stimulating hormone therapy for anovulation in polycystic ovary syndrome.

Authors:  Sophie Catteau-Jonard; Pascal Pigny; Anne-Céline Reyss; Christine Decanter; Edouard Poncelet; Didier Dewailly
Journal:  J Clin Endocrinol Metab       Date:  2007-08-14       Impact factor: 5.958

10.  Reduced intrafollicular androstenedione and estradiol levels in early-treated prenatally androgenized female rhesus monkeys receiving follicle-stimulating hormone therapy for in vitro fertilization.

Authors:  Daniel A Dumesic; R Dee Schramm; Ian M Bird; Eric Peterson; Ann Marie Paprocki; Rao Zhou; David H Abbott
Journal:  Biol Reprod       Date:  2003-06-11       Impact factor: 4.285

View more
  12 in total

Review 1.  Hyperandrogenic origins of polycystic ovary syndrome - implications for pathophysiology and therapy.

Authors:  David H Abbott; Daniel A Dumesic; Jon E Levine
Journal:  Expert Rev Endocrinol Metab       Date:  2019-02-15

2.  Clustering of PCOS-like traits in naturally hyperandrogenic female rhesus monkeys.

Authors:  D H Abbott; B H Rayome; D A Dumesic; K C Lewis; A K Edwards; K Wallen; M E Wilson; S E Appt; J E Levine
Journal:  Hum Reprod       Date:  2017-04-01       Impact factor: 6.918

Review 3.  Scientific Statement on the Diagnostic Criteria, Epidemiology, Pathophysiology, and Molecular Genetics of Polycystic Ovary Syndrome.

Authors:  Daniel A Dumesic; Sharon E Oberfield; Elisabet Stener-Victorin; John C Marshall; Joop S Laven; Richard S Legro
Journal:  Endocr Rev       Date:  2015-10       Impact factor: 19.871

Review 4.  Animal Models to Understand the Etiology and Pathophysiology of Polycystic Ovary Syndrome.

Authors:  Elisabet Stener-Victorin; Vasantha Padmanabhan; Kirsty A Walters; Rebecca E Campbell; Anna Benrick; Paolo Giacobini; Daniel A Dumesic; David H Abbott
Journal:  Endocr Rev       Date:  2020-07-01       Impact factor: 19.871

5.  Exposure of female macaques to Western-style diet with or without chronic T in vivo alters secondary follicle function during encapsulated 3-dimensional culture.

Authors:  Jing Xu; Whitney K McGee; Cecily V Bishop; Byung S Park; Judy L Cameron; Mary B Zelinski; Richard L Stouffer
Journal:  Endocrinology       Date:  2014-12-29       Impact factor: 4.736

Review 6.  Physiological and Pathological Androgen Actions in the Ovary.

Authors:  Olga Astapova; Briaunna M N Minor; Stephen R Hammes
Journal:  Endocrinology       Date:  2019-05-01       Impact factor: 4.736

Review 7.  Mechanisms of intergenerational transmission of polycystic ovary syndrome.

Authors:  Daniel A Dumesic; Luis R Hoyos; Gregorio D Chazenbalk; Rajanigandha Naik; Vasantha Padmanabhan; David H Abbott
Journal:  Reproduction       Date:  2020-01       Impact factor: 3.906

Review 8.  Nonhuman primate models of polycystic ovary syndrome.

Authors:  David H Abbott; Lindsey E Nicol; Jon E Levine; Ning Xu; Mark O Goodarzi; Daniel A Dumesic
Journal:  Mol Cell Endocrinol       Date:  2013-01-29       Impact factor: 4.102

Review 9.  In utero Androgen Excess: A Developmental Commonality Preceding Polycystic Ovary Syndrome?

Authors:  David H Abbott; Marissa Kraynak; Daniel A Dumesic; Jon E Levine
Journal:  Front Horm Res       Date:  2019-09-09       Impact factor: 2.606

Review 10.  Ovarian Follicular Theca Cell Recruitment, Differentiation, and Impact on Fertility: 2017 Update.

Authors:  JoAnne S Richards; Yi A Ren; Nicholes Candelaria; Jaye E Adams; Aleksandar Rajkovic
Journal:  Endocr Rev       Date:  2018-02-01       Impact factor: 19.871

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.